The Range

KPV · Pen · Immune & mucosal research

KPV 5 mg pen

Research-onlyEvidence: Preclinical

A tripeptide fragment of alpha-MSH studied in preclinical inflammation and mucosal immunity research.

KPV pen presentation
KPV research vial presentation
KPV carton and printed panels
Mucosal and immune cell surfaces settling — illustrative science visual.

Evidence highlights

What it is

KPV is the lysine-proline-valine tripeptide, a C-terminal fragment of alpha-melanocyte-stimulating hormone. It is a research compound, not a registered medicine.

Mechanism being studied

Preclinical work describes anti-inflammatory signalling effects, including modulation of NF-kB-related pathways in cell and animal models.

Human evidence

Controlled human evidence is not available. Claims relating to inflammatory or gastrointestinal conditions are not supported for clinical use.

Full research summary

Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.

South Africa — compliance notice

SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.